Kamura Haruka Nakagawa, Yamaguchi Tetsuo, Kasama Toshihiro, Hayashi Yukitaka, Hamada Masakaze, Matsumoto Kazuaki, Miyake Ryo, Ishii Yoshikazu
Microbial Genomics and Ecology, Center for the Planetary Health and Innovation Science (PHIS), The IDEC Institute, Hiroshima University, Hiroshima, Japan.
Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo, Japan.
J Antibiot (Tokyo). 2025 May 7. doi: 10.1038/s41429-025-00826-7.
Lascufloxacin (LSFX) achieves concentrations in epithelial lining fluid (ELF) that are more than 15 times higher than those in the bloodstream, making it a promising candidate for respiratory and otorhinolaryngological infections. These concentrations were replicated using the Hollow-Fiber Infection Model and demonstrated bactericidal efficacy of LSFX against levofloxacin-sensitive and -resistant Streptococcus pneumoniae. The study confirms that LSFX's elevated concentration in ELF plays a significant role in its bactericidal activity.
拉苏氟沙星（LSFX）在上皮衬液（ELF）中的浓度比在血液中的浓度高出15倍以上，这使其成为呼吸道和耳鼻喉感染的一个有前景的候选药物。这些浓度通过中空纤维感染模型得到了重现，并证明了LSFX对左氧氟沙星敏感和耐药的肺炎链球菌具有杀菌效果。该研究证实，LSFX在ELF中的高浓度在其杀菌活性中起重要作用。
